Loosening chimeric antigen receptor's grip on T-regulatory cells improves function, researchers find
A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the "rules" for engineering chimeric antigen receptor (CAR) Tregs. Tregs, or T-regulatory cells, have shown promise in ...
Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...
The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...
Immunotherapy for high grade CNS tumors including adult glioblastoma, anaplastic astrocytoma, pediatric high-grade gliomas, ependymoma and medulloblastoma ...
A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...
Please provide your email address to receive an email when new articles are posted on . After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor ...
CTD402, an allogeneic CAR T-cell therapy, is designed for immediate administration and targets relapsed/refractory T-ALL and ...
MedPage Today on MSN
CAR-T immune toxicity linked to non-relapse mortality risk in myeloma
Study suggests CD4+ T cells mediate these immune-related toxicities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results